Venture Capital

Immunicom Secures $11M In Series B Investment Round

by posted 1year ago 30 views
SAN DIEGO, July 2, 2019-- Immunicom, Inc., a biotechnology company awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating late-stage metastatic cancer, raised $11 million in a Series B investment round. Several private equity family offices participated in the Series B financing which now increases Immunicom's overall capital raised to $20 million. "Proceeds from this financing will help fund the 170-patient, randomized, multi-center, triple-negative breast cancer clinical trial we began May 31, while also fueling continued expansion of Immunicom's global strategic partnerships," said Amir Jafri, the company's Founder and CEO.

In this article